Expression of MACC1 and c-Met in human gastric cancer and its clinical significance

Cancer Cell International

Volumn 13, Issue 1, 2013, Pages

  Guo, Tiankang ^a   Yang, Jingyu ^b   Yao, Jibin ^a   Zhang, Yongbin ^c   Da, Mingxu ^a   Duan, Yaoxing ^c  

^a GANSU PROVINCIAL HOSPITAL   (China)

^b Shandong Institute of Parasitic Diseases   (China)

^c NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

c Met; Gastric cancer; Hepatic metastasis; Lymph node metastasis; Metastasis associated with colon cancer1; Peritoneal metastasis

Indexed keywords

PROTEIN MACC1; SCATTER FACTOR RECEPTOR; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CORRELATION ANALYSIS; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; PERITONEUM METASTASIS; PROTEIN EXPRESSION; STOMACH CANCER; SURVIVAL RATE; TUMOR VOLUME;

EID: 84889805198     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-13-121     Document Type: Article

References (31)

1. Tavares A, Gandra A, Viveiros F, Cidade C, Maciel J. Analysis of clinicopathologic characteristics and prognosis of gastric cancer in young and older patients. Pathol Oncol Res 2013, 19:111-117. 10.1007/s12253-012-9530-z, 22573278.
2. Lin YS, Ueda J, Kikuchi S, Totsuka Y, Wei WQ, Qiao YL, Inoue M. Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol 2011, 17:4421-4428. 10.3748/wjg.v17.i39.4421, 3218157, 22110269.
3. Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, Birchmeier W, Schlag PM. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 2009, 15:59-67. 10.1038/nm.1889, 19098908.
4. Da MX, Wu Z, Tian HW. Tumor lymphangiogenesis and lymphangiogenic growth factors. Arch Med Res 2008, 39:365-372. 10.1016/j.arcmed.2007.12.005, 18375246.
5. Zhou HY, Pon YL, Wong AS. HGF/MET signaling in ovarian cancer. Curr Mol Med 2008, 8:469-480. 10.2174/156652408785747933, 18781954.
6. Ogunwobi OO, Liu C. Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin Exp Metastasis 2011, 28(8):721-731. 10.1007/s10585-011-9404-x, 3732749, 21744257.
7. Gumustekin M, Kargi A, Bulut G, Gozukizil A, Ulukus C, Oztop I, Atabey N. HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer. Pathol Oncol Res 2012, 18(2):209-218. 10.1007/s12253-011-9430-7, 21779788.
8. Kim CH, Koh YW, Han JH, Kim JW, Lee JS, Baek SJ, Hwang HS, Choi EC. c-Met expression as an indicator of survival outcome in patients with oral tongue carcinoma. Head Neck 2010, 32:1655-1664. 10.1002/hed.21383, 20848408.
9. Amemiya H, Kono K, Itakura J, Tang RF, Takahashi A, An FQ, Kamei S, Iizuka H, Fujii H, Matsumoto Y. c-Met expression in gastric cancer with liver metastasis. Oncology 2002, 63:286-296. 10.1159/000065477, 12381909.
10. Zhang W, Chu Y-Q, Ye Z-Y, Zhao Z-S, Tao H-Q. Expression of hepatocyte growth factor and basic fibroblast growth factor as prognostic indicators in gastric cancer. Anat Rec 2009, 292:1114-1121.
11. Amemiya H, Menolascino F, Pena A. Role of the expression of c-Met receptor in the progression of gastric cancer. Invest Clin 2010, 51:369-380.
12. Shimokawa H, Uramoto H, Onitsuka T, Chundong G, Hanagiri T, Oyama T, Yasumoto K. Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence. J Thorac Cardiovasc Surg 2011, 141:895-898. 10.1016/j.jtcvs.2010.09.044, 21093878.
13. Chundong G, Uramoto H, Onitsuka T, Shimokawa H, Iwanami T, Nakagawa M, Oyama T, Tanaka F. Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis. Anticancer Res 2011, 31:1141-1145.
14. Gu C, Uramoto H, Onitsuka T, Shimokawa H, Iwanami T, Nakagawa M, Oyama T, Tanaka F. Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis. Anticancer Res 2011, 31:1141-1145.
15. Shirahata A, Fan W, Sakuraba K, Yokomizo K, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, et al. MACC 1 as a marker for vascular invasive hepatocellular carcinoma. Anticancer Res 2011, 31:777-780.
16. Qiu J, Huang P, Liu Q, Hong J, Li B, Lu C, Wang L, Wang J, Yuan Y. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med 2011, 9:166. 10.1186/1479-5876-9-166, 3192685, 21955323.
17. Huang HL, Shi HR, Zhang RT, Chen ZM, Liu HN, Yuan ZF. Expression of MACC1 in epithelial ovarian cancer and its clinical significance. Tumor 2011, 31:522-526.
18. Zhang R, Shi H, Chen Z, Wu Q, Ren F, Huang H. Effects of metastasis-associated in colon cancer 1 inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells. J Exp Clin Cancer Res 2011, 30:83. 10.1186/1756-9966-30-83, 3182136, 21923915.
19. Boardman LA. Overexpression of MACC1 leads to downstream activation of HGF/MET and potentiates metastasis and recurrence of colorectal cancer. Genome Med 2009, 1:36. 10.1186/gm36, 2684657, 19341507.
20. Li Y, Chen CQ, He YL, Cai SR, Yang DJ, He WL, Xu JB, Zan WH. Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma. J Surg Oncol 2012, 106(3):304-310. 10.1002/jso.23008, 22231933.
21. Kajiya K, Hirakawa S, Ma B, Drinnenberg I, Detmar M. Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J 2005, 24:2885-2895. 10.1038/sj.emboj.7600763, 1187946, 16052207.
22. Zhang QH, Qian K, Li XJ, Pu J, Wu XT. Experimental study of the hepatocyte growth factor contributing to lymphangiogenesis and lymphatic metastasis in gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi 2007, 10:212-216.
23. Glockzin G, Piso P. Current status and future directions in gastric cancer with peritoneal dissemination. Surg Oncol Clin N Am 2012, 21:625-633. 10.1016/j.soc.2012.07.002, 23021720.
24. Shirahata A, Sakata M, Kitamura Y, Sakuraba K, Yokomizo K, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, et al. MACC 1 as a marker for peritoneal-disseminated gastric carcinoma. Anticancer Res 2010, 30:3441-3444.
25. Toiyama Y, Yasuda H, Saigusa S, Matushita K, Fujikawa H, Tanaka K, Mohri Y, Inoue Y, Goel A, Kusunoki M. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int J Cancer 2012, 130:2912-2921. 10.1002/ijc.26330, 21796631.
26. van Denderen BJ, Thompson EW. Cancer: the to and fro of tumour spread. Nature 2013, 493:487-488. 10.1038/493487a, 23344357.
27. Theveneau E, Mayor R. Collective cell migration of epithelial and mesenchymal cells. Cell Mol Life Sci 2013, 70(19):3481-3492. 10.1007/s00018-012-1251-7, 23314710.
28. Jerraya H, Saidani A, Khalfallah M, Bouasker I, Nouira R, Dziri C. Management of liver metastases from gastric carcinoma: where is the evidence?. Tunis Med 2013, 91:1-5.
29. Kodera Y. Treatment strategy for liver metastasis from gastric cancer. Nihon Geka Gakkai Zasshi 2012, 113:22-25.
30. Ge SH, Wu XJ, Wang XH, Xing XF, Zhang LH, Zhu YB, Du H, Dong B, Hu Y, Ji JF. Over-expression of metastasis-associated in colon cancer-1 (MACC1) associates with better prognosis of gastric cancer patients. Chin J Canc Res 2011, 23:153-159.
31. Stein U, Smith J, Walther W, Arlt F. MACC1 controls Met: what a difference an Sp1 site makes. Cell Cycle 2009, 8:2467-2469. 10.4161/cc.8.15.9018, 19556890.